Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIEW Therapies for Meibomian Gland Dysfunction
NCT05577910Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Randomised, single-blind trial in meibomian gland dysfunction (MGD) (3 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Tear Film Breakup Time at 15 months. Started Oct 2022; status: completed.
02
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT05577910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577910.